Celularity Inc.
CELU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.12 | 0.19 |
| FCF Yield | -14.41% | -97.12% | -79.29% | -18.25% |
| EV / EBITDA | -2.60 | -0.59 | 9.84 | -7.16 |
| Quality | ||||
| ROIC | -44.94% | -166.01% | -6.79% | -27.90% |
| Gross Margin | 72.36% | 29.66% | -9.40% | 54.76% |
| Cash Conversion Ratio | 0.11 | 0.20 | -9.72 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.49% | 2.20% | 7.98% | 0.30% |
| Free Cash Flow Growth | 84.64% | 70.14% | -23.06% | -27.76% |
| Safety | ||||
| Net Debt / EBITDA | -1.56 | -0.35 | 2.19 | 0.07 |
| Interest Coverage | -6.12 | -63.78 | 0.00 | -34.39 |
| Efficiency | ||||
| Inventory Turnover | 2.77 | 2.78 | 0.44 | 0.37 |
| Cash Conversion Cycle | -344.31 | 3.01 | 63.58 | 113.53 |